This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.
April 2012
·
16 Reads
The Journal of family practice
For most patients with purulent nasal discharge, antibiotics don't decrease symptom duration; they do increase adverse events. Researchers in the field don't recommend using antibiotics as routine treatment for purulent rhinorrhea associated with symptoms of upper respiratory infection.
May 2011
·
36 Reads
·
4 Citations
American Family Physician
Clinical Inquiries provides answers to questions submitted by practicing family physicians to the Family Physicians Inquiries Network (FPIN). Members of the network select questions based on their relevance to family medicine. Answers are drawn from an approved set of evidence-based resources and undergo peer review. The strength of recommendations and the level of evidence for individual studies are rated using criteria developed by the Evidence-Based Medicine Working Group
January 2009
·
46 Reads
·
2 Citations
The Journal of family practice
Prophylactic oxytocin is fine before or after placental delivery. Timing alone doesn't influence the drug's efficacy in preventing postpartum bleeding (recommendation based on randomized controlled trial and prospective cohort studies).
... Except for congenital abnormalities and developmental delays, for which the data was interpreted as conflicting, physicians were more likely to indicate that adverse fetal and neonatal outcomes had no evidence of an association or evidence of no association with SSRI use overall. Although available data suggests low overall risk of teratogenic effects due to antidepressant use, risks for harm have been found (Patel et al. 2011;Reefhuis et al. 2015;Lattimore et al. 2005), and the FDA's current position is that the "potential risk with SSRI use during pregnancy remains unknown" (US FDA 2012). Fig. 3 Responses to "What is your interpretation of the current evidence on the impact of SSRI use during pregnancy on the listed fetal and neonatal outcomes?" ...
May 2011
American Family Physician
... Oxytocin acts quickly and effectively with minimal adverse effects and can be used in all women, which makes it the main interven- tion for reducing PPH and is the first uterotonic drug option (23). The administration of oxytocin during the TSL reduces the risk of PPH by 40% (24). Immediately after fetal delivery, starting intravenous infusion of 20 IU of oxytocin in 500 mL RL and given within 2 hours is the routine protocol in our institute for AMTSL. ...
January 2009
The Journal of family practice
